788 related articles for article (PubMed ID: 27703344)
1. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
2. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
3. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
4. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
[TBL] [Abstract][Full Text] [Related]
5. Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD.
Cheng SL; Wang HH; Lin CH
Int J Chron Obstruct Pulmon Dis; 2017; 12():2231-2238. PubMed ID: 28814851
[TBL] [Abstract][Full Text] [Related]
6. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
Wang CY; Lai CC; Yang WC; Lin CC; Chen L; Wang HC; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2775-2783. PubMed ID: 27877031
[TBL] [Abstract][Full Text] [Related]
7. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
Pavord ID; Lettis S; Anzueto A; Barnes N
Lancet Respir Med; 2016 Sep; 4(9):731-741. PubMed ID: 27460163
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
Song JH; Lee CH; Kim JW; Lee WY; Jung JY; Park JH; Jung KS; Yoo KH; Park YB; Kim DK
Int J Chron Obstruct Pulmon Dis; 2017; 12():2455-2464. PubMed ID: 28860740
[TBL] [Abstract][Full Text] [Related]
9. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449
[TBL] [Abstract][Full Text] [Related]
10. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia.
Cheng SL; Su KC; Wang HC; Perng DW; Yang PC
Drug Des Devel Ther; 2014; 8():601-7. PubMed ID: 24920884
[TBL] [Abstract][Full Text] [Related]
11. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
12. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.
Barnes NC; Sharma R; Lettis S; Calverley PM
Eur Respir J; 2016 May; 47(5):1374-82. PubMed ID: 26917606
[TBL] [Abstract][Full Text] [Related]
13. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD.
Mathioudakis AG; Bikov A; Foden P; Lahousse L; Brusselle G; Singh D; Vestbo J
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32108044
[TBL] [Abstract][Full Text] [Related]
14. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.
Morjaria JB; Rigby A; Morice AH
Lung; 2017 Jun; 195(3):281-288. PubMed ID: 28255905
[TBL] [Abstract][Full Text] [Related]
15. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Lung; 2006; 184(4):217-22. PubMed ID: 17006748
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD.
Contoli M; Pauletti A; Rossi MR; Spanevello A; Casolari P; Marcellini A; Forini G; Gnesini G; Marku B; Barnes N; Rizzi A; Curradi G; Caramori G; Morelli P; Papi A
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 28982774
[TBL] [Abstract][Full Text] [Related]
17. Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.
Rodriguez-Roisin R; Tetzlaff K; Watz H; Wouters EF; Disse B; Finnigan H; Magnussen H; Calverley PM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1973-81. PubMed ID: 27578972
[TBL] [Abstract][Full Text] [Related]
18. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
19. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
Papi A; Jones PW; Dalvi PS; McAulay K; McIver T; Dissanayake S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2431-8. PubMed ID: 26648706
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.
Lee SY; Park HY; Kim EK; Lim SY; Rhee CK; Hwang YI; Oh YM; Lee SD; Park YB
Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
